G. Hutter, D. Nowak, M. Mossner, S. Ganepola, A. Mussig et al.,

O. Kucherer, I. W. Blau, W. K. Blau, E. Hofmann, and . Thiel, Long-term control of HIV by CCR5 Delta32/Delta32 559 stem-cell transplantation, N Engl J Med, vol.360, pp.692-698, 2009.

R. Liu, W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin et al.,

A. Koup and N. R. Landau, Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed 562 individuals to HIV-1 infection, Cell, vol.86, pp.367-377, 1996.

M. Samson, F. Libert, B. J. Doranz, J. Rucker, C. Liesnard et al., , p.564

J. Cognaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy et al.,

J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, and M. Parmentier, Resistance to HIV-1 infection in caucasian 566 individuals bearing mutant alleles of the CCR-5 chemokine receptor gene, Nature, vol.382, pp.722-725, 1996.

R. K. Gupta, S. Abdul-jawad, L. E. Mccoy, H. P. Mok, D. Peppa et al., , p.568

A. M. Nijhuis, H. Wensing, P. Lee, E. Grant, J. Nastouli et al.,

L. Muir, J. Waters, A. M. Frater, S. G. Lever, I. H. Edwards et al.,

M. Boeckh, W. Leisenring, S. R. Riddell, R. A. Bowden, M. L. Huang et al.,

E. Flowers, T. Cunningham, and L. Corey, Late cytomegalovirus disease and mortality in recipients of allogeneic 609 hematopoietic stem cell transplants: importance of viral load and T-cell immunity, Blood, vol.101, p.15, 2003.

A. Knoll, S. Boehm, J. Hahn, E. Holler, and W. Jilg, Long-term surveillance of haematopoietic stem cell 611 recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor, J 612 Viral Hepat, vol.14, pp.478-483, 2007.

J. W. Van-esser, B. Van-der-holt, E. Meijer, H. G. Niesters, R. Trenschel et al.,

A. Frassoni, U. W. Bacigalupo, A. D. Schaefer, J. W. Osterhaus, B. Gratama et al., J. J, p.615

E. Cornelissen and . Virus, EBV) reactivation is a frequent event after allogeneic stem cell transplantation 616 (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT, Blood, vol.98, pp.972-617, 2001.

C. M. Bollard and H. E. Heslop, T cells for viral infections after allogeneic hematopoietic stem cell transplant, Blood, vol.619, pp.3331-3340, 2016.

A. M. Leen, H. E. Heslop, and M. K. Brenner, Antiviral T-cell therapy, Immunol Rev, vol.258, p.19, 2014.

P. Moss and A. Rickinson, Cellular immunotherapy for viral infection after HSC transplantation, Nat Rev 622 Immunol, vol.5, pp.9-20, 2005.

T. J. Henrich, E. Hanhauser, F. M. Marty, M. N. Sirignano, S. Keating et al.,

J. Z. Davis, A. Li, A. L. Heisey, M. P. Hill, P. Busch et al., , p.625

, Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases

, Ann Intern Med, vol.161, pp.319-327, 2014.

M. Rothenberger, J. E. Wagner, A. Haase, D. Richman, B. Grzywacz et al.,

A. T. Fletcher, J. Podany, T. Anderson, S. Schmidt, T. Wietgrefe et al., Transplantation of 629 CCR532 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally 630

, Acquired HIV Infection. Open forum infectious diseases, vol.5, p.90, 2018.

C. P. Passaes and A. Saez-cirion, HIV cure research: advances and prospects. Virology 454-455, p.632, 2014.
URL : https://hal.archives-ouvertes.fr/pasteur-01420527

A. Alousi, T. Wang, M. T. Hemmer, S. R. Spellman, M. Arora et al., , p.634

C. N. Boyiadzis, J. Y. Bredeson, M. S. Cahn, S. M. Cairo, S. K. Gadalla et al.,

M. A. Kamble, M. R. Kharfan-dabaja, O. Litzow, A. A. Ringden, K. R. Saad et al.,

J. A. Waller, S. G. Yared, D. J. Holtan, and . Weisdorf, Peripheral Blood versus Bone Marrow from Unrelated Donors: 637 Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, p.638

, Survival. Biol Blood Marrow Transplant, vol.25, pp.270-278, 2019.

C. Anasetti, B. R. Logan, S. J. Lee, E. K. Waller, D. J. Weisdorf et al., , p.640

A. Woolfrey, S. Couban, G. Ehninger, L. Johnston, R. T. Maziarz et al., , p.641

S. P. Mccarty, P. Khan, W. I. Anderlini, S. F. Bensinger, S. D. Leitman et al., , p.642

D. L. Horowitz, . Confer, and N. Blood, Marrow Transplant Clinical Trials, Peripheral-blood stem cells versus bone 643 marrow from unrelated donors, N Engl J Med, vol.367, p.25, 2012.

R. F. Ambinder, J. Wu, B. Logan, C. M. Durand, R. Shields et al., , p.645

J. W. Cyktor, E. Mellors, L. D. Ayala, A. Kaplan, R. J. Noy et al., , p.646

P. Lara, L. Shaughnessy, S. K. Sproat, A. M. Hashmi, M. M. Mendizabal et al., , p.647

, Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: the BMT CTN-648

, Trial. Biol Blood Marrow Transplant, 2019.

G. Hutter and J. A. Zaia, Allogeneic haematopoietic stem cell transplantation in patients with human 650 immunodeficiency virus: the experiences of more than 25 years, Clin Exp Immunol, vol.163, p.27, 2011.

J. Ogonek, M. Juric, S. Ghimire, P. R. Varanasi, E. Holler et al., Immune 652 Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation, Front Immunol, vol.7, p.28, 2016.

M. R. Van-den, E. Brink, M. A. Velardi, and . Perales, Immune reconstitution following stem cell transplantation

, Hematology Am Soc Hematol Educ Program, pp.215-219, 2015.

C. Heining, A. Spyridonidis, E. Bernhardt, J. Schulte-monting, D. Behringer et al., , p.656

J. Bertz and . Finke, Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a 657 retrospective study including 148 patients, Bone Marrow Transplant, vol.39, pp.613-622, 2007.

T. J. Fry and C. L. Mackall, Immune reconstitution following hematopoietic progenitor cell transplantation: 659 challenges for the future, Bone Marrow Transplant, vol.35, pp.53-57, 2005.

W. Krenger, B. R. Blazar, and G. A. Hollander, Thymic T-cell development in allogeneic stem cell 661 transplantation, Blood, vol.117, pp.6768-6776, 2011.

C. D. Surh and J. Sprent, Homeostasis of naive and memory T cells, Immunity, vol.29, pp.848-862, 2008.

S. J. Lin, C. D. Peacock, K. Bahl, and R. M. Welsh, Programmed death-1 (PD-1) defines a transient and 664 dysfunctional oligoclonal T cell population in acute homeostatic proliferation, J Exp Med, vol.204, p.34, 2007.

A. Saha, K. Aoyama, P. A. Taylor, B. H. Koehn, R. G. Veenstra et al.,

J. Murphy, M. Azuma, H. Yagita, B. T. Fife, M. H. Sayegh et al.,

B. R. Sharpe and . Blazar, Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in 668 regulating graft-versus-host disease lethality, Blood, vol.122, pp.3062-3073, 2013.

A. Sivro, A. Schuetz, D. Sheward, V. Joag, S. Yegorov et al.,

P. Mwatelah, N. Selhorst, N. Garrett, A. Samsunder, F. Balgobin et al.,

J. Anzala, B. S. Kimani, N. Bagaya, C. Kiwanuka, R. Williamson et al., , p.672

A. Ananworanich, Q. Ansari, S. S. Karim, L. R. Karim, . Mckinnon et al., , p.673

, Integrin alpha4beta7 expression on peripheral blood CD4(+) T cells predicts HIV acquisition and disease 674 progression outcomes, Sci Transl Med, vol.10, 2018.

M. R. Betts, M. C. Nason, S. M. West, S. C. De-rosa, S. A. Migueles et al., , p.676

P. A. Benito, M. Goepfert, M. Connors, R. A. Roederer, and . Koup, HIV nonprogressors preferentially maintain highly 677 functional HIV-specific CD8+ T cells, Blood, vol.107, pp.4781-4789, 2006.

V. Appay, L. Papagno, C. A. Spina, P. Hansasuta, A. King et al., , p.679

D. D. Richman and S. L. Rowland-jones, Dynamics of T cell responses in HIV infection, J Immunol, vol.168, p.680, 2002.

W. Zhou, J. Longmate, S. F. Lacey, J. M. Palmer, G. Gallez-hawkins et al.,

S. J. Nakamura, J. A. Forman, D. J. Zaia, and . Diamond, Impact of donor CMV status on viral infection and 683 reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients, Blood, vol.113, pp.6465-6476, 2009.

M. S. Chaudhry, E. Velardi, F. Malard, M. R. Van-den, and . Brink, Immune Reconstitution after Allogeneic, vol.686

, Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus, J Immunol, vol.198, p.40, 2017.

P. Ye, D. E. Kirschner, and A. P. Kourtis, The thymus during HIV disease: role in pathogenesis and in immune 688 recovery, Current HIV research, vol.2, pp.177-183, 2004.

B. M. Grogan, L. Tabellini, B. Storer, T. E. Bumgarner, C. C. Astigarraga et al., , p.690

E. H. Martin, J. A. Warren, and . Hansen, Activation and expansion of CD8(+) T effector cells in patients with chronic 691 graft-versus-host disease, Biol Blood Marrow Transplant, vol.17, pp.1121-1132, 2011.

P. Khandelwal, V. Chaturvedi, E. Owsley, A. Lane, D. Heyenbruch et al.,

A. S. Grimley, S. M. Nelson, M. B. Davies, R. A. Jordan, and . Marsh, CD38(bright)CD8(+) T Cells Associated with the 694 Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells, Biol Blood Marrow, vol.695, 2019.

M. Paz-morante, J. Briones, E. Canto, H. Sabzevari, R. Martino et al.,

. Vidal, Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease, Clin Exp Immunol, vol.145, pp.36-43, 2006.

N. Chomont, M. El-far, P. Ancuta, L. Trautmann, F. A. Procopio et al.,

G. Boulassel, J. M. Ghattas, T. W. Brenchley, B. J. Schacker, D. C. Hill et al.,

. Sekaly, HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation, Nat Med, vol.15, pp.893-900, 2009.

F. R. Simonetti, M. D. Sobolewski, E. Fyne, W. Shao, J. Spindler et al.,

S. Watters, X. Hill, D. Wu, L. Wells, B. T. Su et al., , p.705

C. Van-waes, T. Uldrick, D. E. Citrin, J. Kovacs, M. A. Polis et al.,

F. Kearney, J. M. Coffin, S. H. Hughes, J. W. Mellors, and F. Maldarelli, Clonally expanded CD4+ T cells can produce 707 infectious HIV-1 in vivo, Proc Natl Acad Sci U S A, vol.113, pp.1883-1888, 2016.

R. H. Moy, A. P. Huffman, L. P. Richman, L. Crisalli, X. K. Wang et al., , p.709

Y. Zhang, R. H. Vonderheide, D. L. Porter, and R. Reshef, Clinical and immunologic impact of CCR5 blockade in graft-710 versus-host disease prophylaxis, Blood, vol.129, pp.906-916, 2017.

A. E. Woolfrey, U. Malhotra, R. D. Harrington, J. Mcnevin, T. J. Manley et al.,

R. Appelbaum, L. Corey, and R. Storb, Generation of HIV-1-specific CD8+ cell responses following allogeneic 713 hematopoietic cell transplantation, Blood, vol.112, pp.3484-3487, 2008.

L. Colonna, C. W. Peterson, J. B. Schell, J. M. Carlson, V. Tkachev et al., , p.715

V. Obenza, P. S. Nelson, H. Polacino, S. L. Mack, K. Hu et al., , p.716

A. Taraseviciute, D. J. Hunt, K. Betz, J. F. Lane, K. Vogel et al.,

C. Murnane, C. A. English, S. Astley, B. Wangari, J. Agricola et al.,

K. R. Huang, H. P. Jerome, L. S. Kiem, and . Kean, Evidence for persistence of the SHIV reservoir early after MHC 719 haploidentical hematopoietic stem cell transplantation, Nat Commun, vol.9, p.4438, 2018.

J. P. Grob, J. E. Grundy, H. G. Prentice, P. D. Griffiths, A. V. Hoffbrand et al.,

M. K. Wimperis and . Brenner, Immune donors can protect marrow-transplant recipients from severe cytomegalovirus 722 infections, Lancet, vol.1, pp.774-776, 1987.

G. K. Lau, R. Liang, C. K. Lee, S. T. Yuen, J. Hou et al., Clearance of persistent 724 hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core-725 and anti-hepatitis B surface antibody-positive, J Infect Dis, vol.178, p.51, 1998.

R. Liang, How I treat and monitor viral hepatitis B infection in patients receiving intensive 727 immunosuppressive therapies or undergoing hematopoietic stem cell transplantation, Blood, vol.113, p.52, 2009.

P. Reusser, S. R. Riddell, J. D. Meyers, and P. D. Greenberg, Cytotoxic T-lymphocyte response to 729 cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with 730 cytomegalovirus infection and disease, Blood, vol.78, pp.1373-1380, 1991.

D. Koning, A. I. Costa, I. Hoof, J. J. Miles, N. M. Nanlohy et al., , p.732

J. A. Schellens, C. Borghans, D. A. Kesmir, D. Price, and . Van-baarle, CD8+ TCR repertoire formation is guided 733 primarily by the peptide component of the antigenic complex, J Immunol, vol.190, pp.931-939, 2013.

M. R. Von-essen, M. Kongsbak, and C. Geisler, Mechanisms behind functional avidity maturation in T cells

, Clin Dev Immunol, vol.2012, p.163453, 2012.

A. L. Hill, D. I. Rosenbloom, E. Goldstein, E. Hanhauser, D. R. Kuritzkes et al., , p.737

, Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for 738 HIV, PLoS Pathog, vol.12, p.1005535, 2016.

B. O. Jensen, E. Knops, N. Lübke, A. Wensing, J. Martinez-picado et al., , p.740

T. Harrer, E. Heger, J. M. Eberhard, I. Hauber, C. Münk et al., CROI, vol.741, p.57, 2019.

B. Jensen, D. Haussinger, E. Knops, A. Wensing, J. Martinez-picado et al.,

. Lubke, CROI, 2020.

P. Kongtim, D. A. Lee, L. J. Cooper, P. Kebriaei, R. E. Champlin et al., , p.744

, Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy, Biol Blood 745 Marrow Transplant, vol.21, pp.1714-1720, 2015.

P. J. Hanley, J. J. Melenhorst, S. Nikiforow, P. Scheinberg, J. W. Blaney et al.,

S. Cruz, R. A. Lam, K. S. Krance, C. A. Leung, H. Martinez et al., , p.748

A. J. Shpall, J. R. Barrett, C. M. Rodgers, and . Bollard, CMV-specific T cells generated from naive T cells recognize 749 atypical epitopes and may be protective in vivo, Sci Transl Med, vol.7, pp.285-263, 2015.

T. Kaeuferle, R. Krauss, F. Blaeschke, S. Willier, and T. Feuchtinger, Strategies of adoptive T -cell transfer to 751 treat refractory viral infections post allogeneic stem cell transplantation, J Hematol Oncol, vol.12, p.61, 2019.

M. Caskey, F. Klein, and M. C. Nussenzweig, Broadly neutralizing anti-HIV-1 monoclonal antibodies in the 753 clinic, Nat Med, vol.25, pp.547-553, 2019.

S. Moron-lopez, J. Navarro, M. Jimenez, S. Rutsaert, V. Urrea et al., , p.755

B. P. Ribas, C. Galvez, M. Salgado, L. Vandekerckhove, J. Blanco et al., Switching From 756 a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine 757 the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human 758 Immunodeficiency Virus-infected Individuals, Clin Infect Dis, vol.69, pp.1320-1328, 2019.

A. Amendola, M. Bloisi, P. Marsella, R. Sabatini, A. Bibbo et al., , p.760

, Standardization and performance evaluation of "modified" and "ultrasensitive" versions of the Abbott RealTime 761 HIV-1 assay, adapted to quantify minimal residual viremia, J Clin Virol, vol.52, pp.17-22, 2011.

K. J. Bosman, A. M. Wensing, A. E. Pijning, W. J. Van-snippenberg, P. M. Van-ham et al.,

M. Hoepelman and . Nijhuis, Development of sensitive ddPCR assays to reliably quantify the proviral DNA reservoir in 764 all common circulating HIV subtypes and recombinant forms, J Int AIDS Soc, vol.21, p.25185, 2018.

J. M. Eberhard, F. Ahmad, H. S. Hong, N. Bhatnagar, P. Keudel et al.,

. Meyer-olson, Partial recovery of senescence and differentiation disturbances in CD8(+) T cell effector-memory 767 cells in HIV-1 infection after initiation of anti-retroviral treatment, Clin Exp Immunol, vol.186, p.66, 2016.

A. I. Lazarovits, R. A. Moscicki, J. T. Kurnick, D. Camerini, A. K. Bhan et al., , p.769

. Colvin, Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte 770 activation antigen, J Immunol, vol.133, pp.1857-1862, 1984.

F. Sallusto, J. Geginat, and A. Lanzavecchia, Central memory and effector memory T cell subsets: function, 772 generation, and maintenance, Annu Rev Immunol, vol.22, pp.745-763, 2004.